Accelerated Approval Does Not Accelerate ACIP Recommendation For Prevnar 13 In Adults
Pfizer still plans to launch Prevnar 13 for adults 50 and older absent an ACIP treatment recommendation, creating an interesting situation for physicians.
You may also be interested in...
New post-marketing commitment will look at conjugate pneumonia vaccine when given in patients 50 and older who have already received Merck’s polysaccharide vaccine.
From surprisingly contentious to surprisingly unanimous, VRBPAC's favorable votes have grown from 17 to 21 over the course of three meetings on coronavirus vaccines.
More than 5% of participants in J&J’s vaccine trial chose to be unblinded because they were eligible to receive a vaccine that had already gained a US FDA emergency use authorization.